Lower insulin sensitivity remains a feature of children born very preterm

Valentina Chiavaroli1,2, José G B Derraik1,3,4,5, Thilini N Jayasinghe1

  • 1Liggins Institute, University of Auckland, Auckland, New Zealand.

Pediatric Diabetes
|October 21, 2020
PubMed

Insights

Children born very preterm still exhibit lower insulin sensitivity compared to term-born peers, indicating a persistent metabolic challenge. This finding highlights the long-term health implications for extremely premature infants despite advances in neonatal care.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Health

Background:

  • Previous reports indicated insulin resistance in children born very preterm (<32 weeks gestation).
  • Neonatal care has significantly improved since the initial reports.
  • The current study investigates persistent insulin sensitivity differences in this population.

Purpose of the Study:

  • To assess if children born very preterm still demonstrate lower insulin sensitivity compared to term-born controls.
  • To evaluate metabolic and cardiovascular parameters in prepubertal children born very preterm.

Main Methods:

  • Inclusion of prepubertal children aged 5-11 years, born very preterm (n=51) or at term (n=50).
  • Utilized frequently sampled intravenous glucose tolerance tests and Bergman's minimal model for insulin sensitivity calculation.
  • Conducted anthropometry, body composition analysis, and blood pressure monitoring (clinic and 24-hour ambulatory).

Main Results:

  • Children born very preterm were smaller and had lower BMI SDS compared to term controls.
  • Insulin sensitivity was 25% lower in the very preterm group (P=.001).
  • Awake systolic blood pressure tended to be higher in the very preterm group (P=.054), with significantly higher clinic systolic blood pressure (P=.002).

Conclusions:

  • Lower insulin sensitivity persists in children born very preterm, even with improved neonatal care.
  • The findings suggest a primarily peripheral defect in insulin action, not hepatic.
  • These results underscore the need for continued monitoring of metabolic health in this population.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.8K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
133
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
105
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
513